Eplerenone - Warnings and Precautions
The following warnings and precautions are taken directly from the US FDA-approved drug label for Eplerenone. This is the same information dispensing pharmacists read.
5 WARNINGS AND PRECAUTIONS Hyperkalemia: Patients with decreased renal function, diabetes, proteinuria or patients who are taking ACEs and ARBs, NSAIDs or moderate CYP3A inhibitors are at increased risk.
Monitor serum potassium levels and adjust dose as needed.
5.1 Hyperkalemia The risk of hyperkalemia is higher in patients with impaired renal function, proteinuria, diabetes and those concomitantly treated with ACEs, ARBs, NSAIDs and moderate CYP3A inhibitors.
Minimize the risk of hyperkalemia with proper patient selection and monitoring [see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , ADVERSE REACTIONS , and DRUG INTERACTIONS ].
Monitor patients for the development of hyperkalemia until the effect of eplerenone is established.
Patients who develop hyperkalemia (5.5 mEq/L to 5.9 mEq/L) may continue eplerenone therapy with proper dose adjustment.
Dose reduction decreases potassium levels.
Patients on moderate CYP3A inhibitors that cannot be avoided should have their dose of eplerenone reduced. [see DRUG INTERACTIONS ].
Applies to YOU?
Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 8+ warnings apply to your profile.
Ask Health AI \u2192